I would like to share your optimism, but it comes down to paying for expenses. RVX burns at least $3 million/month.  We are still years away from getting anything acceptable to a big pharma company, as far as a drug is concerned.

The ticket out of this was a strong share price (off the Phase 3 results), which would have created a currency to raise capital. That avenue is now over.  

I looked up Hepalink's financials.  They have accumulated quite a sizable debt level.  They are in no position to fund any more RVX.  Ditto for Ms. Fong.  Dart must be tired of not making money for years.  So who is left?

It is time to sell RVX to another company.